CARsgen Eyes US Filing For Anti-Claudin18.2 CAR-T Therapy

Chinese start-up CARsgen Therapeutics hopes to launch trials in the US for its first-in-class anti-claudin18.2 CAR-T cell therapy. It is also looking at a new round of fundraising to support multiple clinical development programs.